欧洲生物技术收购公司（纳斯达克股票代码：EBAC）认为空头利率大幅增加

European Biotech Acquisition Corp. (NASDAQ:EBAC – Get Rating) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 258,800 shares, an increase of 6,370.0% from the January 31st total of 4,000 shares. Currently, 2.0% of the company's stock are sold short. Based on an average daily trading volume, of 88,600 shares, the days-to-cover ratio is currently 2.9 days.

European Biotech Acquisition Trading Up 19.4 %

Shares of European Biotech Acquisition stock opened at $11.71 on Thursday. European Biotech Acquisition has a 52-week low of $9.28 and a 52-week high of $14.10. The stock has a 50-day simple moving average of $10.17 and a 200-day simple moving average of $10.03.

Institutional Investors Weigh In On European Biotech Acquisition

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in European Biotech Acquisition in the 4th quarter worth approximately $199,000. Exos TFP Holdings LLC acquired a new stake in European Biotech Acquisition in the 3rd quarter worth approximately $357,000. Gritstone Asset Management LLC acquired a new stake in European Biotech Acquisition in the 4th quarter worth approximately $565,000. Cubist Systematic Strategies LLC lifted its holdings in European Biotech Acquisition by 136.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 60,555 shares of the company's stock worth $593,000 after purchasing an additional 34,896 shares during the last quarter. Finally, Calamos Advisors LLC acquired a new stake in European Biotech Acquisition in the 3rd quarter worth approximately $992,000.

About European Biotech Acquisition

(Get Rating)

European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on business in the life sciences industry in Europe.

Recommended Stories

• Get a free copy of the StockNews.com research report on European Biotech Acquisition (EBAC)
• Jack in the Box Pops On Tasty Results, Robust Outlook
• How Low Can Lowe's Companies Go?
• Ambarella: An AI Play In The Making
• Terran Orbital's New $2.4 Billion Contract is a Game Changer
• Wendy's Price Firms After Sizzling Quarter And Juicy Outlook

Receive News & Ratings for European Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for European Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.